Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.

Braig, Friederike

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. [electronic resource] - Oncotarget Jul 2016 - 42988-42995 p. digital

Publication Type: Journal Article

1949-2553

10.18632/oncotarget.8943 doi


Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Squamous Cell--drug therapy
Cell Line, Tumor
Cetuximab--administration & dosage
Drug Resistance, Neoplasm--genetics
ErbB Receptors--antagonists & inhibitors
Fluorouracil--administration & dosage
GTP Phosphohydrolases--genetics
Head and Neck Neoplasms--drug therapy
High-Throughput Nucleotide Sequencing--methods
Humans
Liquid Biopsy--methods
Membrane Proteins--genetics
Mutation--drug effects
Platinum--administration & dosage
Proto-Oncogene Proteins p21(ras)--genetics
ras Proteins--genetics